Kyorin Pharmaceutical Co., Ltd.

Shigeru Izawa

Shigeki Seto

Asao Tanioka

Makoto Ikeda

A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; R is a hydrogen atom, a Cto Calkyl group, a Cto Calkylcarbonyl group, or a Cto Calkylsulfonyl group; m is 1 or 2; and n is 2 or 3.

Fused bicyclic pyrimidine derivatives

A novel fused bicyclic pyridine derivative or a salt thereof that acts as a tachykinin receptor antagonist, in particular as an NK1 receptor antagonist, is represented by the following general formula (1):

Fused bicyclic pyridine derivatives as tachykinin receptor antagonists

A fused bicyclic pyridine derivative represented by the following general formula (1), or a salt thereof:

Fused bicyclic pyridine derivative as tachykinin receptor antagonist

A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1):wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; m is 1 or 2; and n is 2 or 3.

Growing community of inventors

Tochigi, Japan

Shigeru Izawa